Medicare Stands Firm: No Public Coverage for New Alzheimer’s Drugs
Last April, the Centers for Medicare and Medicaid Services (CMS) decided to limit the coverage of the controversial Alzheimer’s drug Aduhelm and similar drugs…
Last April, the Centers for Medicare and Medicaid Services (CMS) decided to limit the coverage of the controversial Alzheimer’s drug Aduhelm and similar drugs…
Leqembi clinical trials are still ongoing, and participants have a 50/50 chance of receiving the $26,500-per-year drug for free. The other half will receive…
Certain medications and health factors could increase your risk of side effects when taking LEQEMBI™ and other monoclonal antibody drugs for Alzheimer’s. Here’s what…
Phil Gutis, a career reporter and writer living with early-onset Alzheimer’s, participated in the clinical trials for the first-ever disease-modifying Alzheimer’s drug. Now, he…
A new disease-modifying Alzheimer’s drug, lecanemab — which will be distributed under the brand name Leqembi — today secured FDA approval. Today, the Food…
Cuba has quietly been developing their own Alzheimer’s treatment. It’s administered nasally. And it’s just entered clinical trials. The United States imposed a blockade…
AmyriAD Therapeutics CEO Sharon L. Rogers shares the scoop on AmyriAD’s investigational Alzheimer’s drug AD101. The majority of experimental Alzheimer’s drugs are being designed…
New trial data presented at CTAD shows drug brexpiprazole is effective at treating agitation in people with Alzheimer’s dementia. The FDA may consider it…
In Phase 3 trials, Roche’s experimental Alzheimer’s drug gantenerumab has failed to meet its objectives for slowing cognitive decline. Most Alzheimer’s treatments on the market…
We looked at all the credible, peer-reviewed studies out there, talked to experts, and got to the bottom of the question about whether or…
Scientists screened 595 FDA-approved drugs to see if they interfered with the activity of gene mutation ApoE4. Two of these — antidepressant imipramine and…
Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…
In a new mouse study, Salk researchers found a drug, CMS121, that appears to treat neurodegeneration in mice. Researchers at the Salk Institute for…
More researchers are paying attention to the therapeutic benefits of psychedelics when it comes to treating mental illnesses like depression and addiction — and…
In a new study, scientists have tested an experimental drug in mice that may hold promise for future Alzheimer’s treatments. The drug involves a…